Antipsychotics deprescribing in schizophrenia: trends and associated characteristics in Belgium and Québec

Background : Antipsychotic polypharmacy (APP) is common worldwide in schizophrenia, while switch to antipsychotic monotherapy reduces adverse effects. Canada has been the leader in deprescribing policies in the last decades. Aims : To detect factors, including countries, associated with successful antipsychotic deprescribing after a psychiatric hospitalisation. Methods : Retrospective data were collected in a tertiary care hospital in Montreal (QC, Canada) and compared to data collected in 6 Belgian hospitals, in 2020-2021. Adult inpatients with a diagnosis of schizophrenia or schizoaffective... Mehr ...